Announcements

  • Pfizer's Trumenba just got closer to a new FDA nod. Can it catch up to GlaxoSmithKline's Bexsero?

    By: Ben Dawes Ben Dawes , 8 years ago
    Hot on the heels of men B rival GlaxoSmithKline, Pfizer's vaccine Trumenba picked up an FDA “breakthrough” designation that could speed its move toward a bigger market.